Research map: Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials

Back to the article

Papers in this map

  1. Neoantigens in cancer immunotherapy · Ton N. Schumacher · 2015 · 4897 citations · Cited by this paper
  2. Temporal linguistic shifts in oncology randomized controlled trials following large language model availability: A corpus analysis of 21,392 publications · 2026 · Related
  3. Clinical development success rates for investigational drugs · Michael Hay · 2014 · 2585 citations · Cited by this paper
  4. Risk of recurrence of stage I to III melanoma in Norway, 2008–2022 · 2026 · Related
  5. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study · Franck Pagès · 2018 · 2134 citations · Cited by this paper
  6. The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients – Results from the UK MRC OE02 trial · 2026 · Related
  7. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination · Jiali Yu · 2021 · 1030 citations · Cited by this paper
  8. Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4) · 2026 · Related
  9. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer · Laura Mezquita · 2018 · 982 citations · Cited by this paper
  10. Letter-to-the-editor Re: “Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC” · 2026 · Related
  11. Dose Escalation Methods in Phase I Cancer Clinical Trials · Christophe Le Tourneau · 2009 · 879 citations · Cited by this paper
  12. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial · 2026 · Related
  13. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies · Mihaela D. Aldea · 2021 · 323 citations · Cited by this paper
  14. Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy · 2026 · Related
  15. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study · Sophie C. Postel-Vinay · 2014 · 124 citations · Cited by this paper
  16. Tumor treating fields: Will the evidence gap ever be filled? · 2026 · Related
  17. Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials · Christophe Le Tourneau · 2010 · 60 citations · Cited by this paper
  18. Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience · 2026 · Related
  19. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability · Toky Ratovomanana · 2023 · 57 citations · Cited by this paper
  20. Management of critically ill cancer patients. Expert consensus statement of the “Intensive Care for Hematology and Oncology Patients” (iCHOP) Working Group of the German Society of Hematology and Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN) · 2026 · Related
  21. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy · Laurent Dercle · 2022 · 44 citations · Cited by this paper
  22. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial · Clélia Coutzac · 2022 · 33 citations · Cited by this paper
  23. Untitled · Cited by this paper
  24. Untitled · Cited by this paper
  25. Untitled · Cited by this paper
  26. Untitled · Cited by this paper
  27. Untitled · Cited by this paper
  28. Untitled · Cited by this paper

Source: OpenAlex (CC0)